Indevus Pharmaceuticals, Inc. has received an approvable letter from FDA for its long-acting depot preparation of testosterone undecanoate (Nebido), which is indicated for the treatment of male hypogonadism.

Manufacturers of fluoroquinolone antimicrobial drugs have been notified by FDA that a boxed warning in the product labeling concerning the increased risk of tendinitis and tendon rupture is necessary.

Results of a study based on data from approximately 43,400 men show risks of developing melanoma and prostate cancer are increased among those with a diagnosis of male factor infertility, reported researchers from the University of California, San Francisco.

Pediatric oncologists appear strongly motivated to preserve fertility in male adolescent cancer patients, although there remains a disconnect between their attitudes and practices with respect to referring patients for available services, according to results of the Survey for Preservation of Adolescent REproduction (SPARE) study.

Increasingly, genetics is changing the way urologists diagnose and treat problems related to male infertility. As lab findings become clinical realities, andrologists and general urologists alike are finding their daily practices changed by advances in our understanding of the human genome.

Men who present with infertility issues and their partners are relatively uninformed about the causes and treatments of male infertility, a fact that may be attributable to urologists' failure to properly market their capabilities in this area of clinical practice.

Data from studies on post-vasectomy clearance suggest that a single azoospermic sample submitted 16 weeks following vasectomy is sufficient to establish the success of the procedure and future sterility.

Two groups have taken innovative steps to match technology with important clinical problems: the microscope with NOA and the Whitaker test with EDO.

Mounting evidence suggests that the appearance of sperm has little to do with its function.